



Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.)
CVR Payment Statement for Quarter Ending June 30, 2026

Line Item	Calculation Ref	Payments to Date Amount	Q2-2026 Proceeds Payment Amount	Prior Holdback Payment Amount (1)	Q2-2026 Total Payment
Gross Proceeds	A	\$ 53,839,970.00	\$ 40,000,000.00	-	\$ 40,000,000.00
Permitted Deductions	B	(6,565,797.21)	-	-	-
Net Proceeds	C = A + B	47,274,172.79	40,000,000.00	-	40,000,000.00
Adjustment Amount	D	(1,000,000.00)	-	-	-
CVR Cash Payment	E = C + D	46,274,172.79	40,000,000.00	-	40,000,000.00
Holdback, per CVR Payment definition	F = E x 15%	(6,941,125.92)	(6,000,000.00)	2,444,508.45	(3,555,491.55)
CVR Payment	G = E + F	39,333,046.87	34,000,000.00	2,444,508.45	36,444,508.45
90% per Section 2.4	H = G x 90%	35,399,742.18	30,600,000.00	2,200,057.61	32,800,057.61
Number of Outstanding CVRs					94,280,501
CVR Payment per Outstanding CVR					\$ 0.347899

(1) Payment relates to the release of holdbacks from prior CVR payments in 2023-25